Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $9.7M | 16 | 100.0% |
| Consulting Fee | $2,100 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lundbeck LLC | $9.7M | 16 | $0 (2024) |
| West Therapeutics Development, LLC | $2,100 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $342,375 | 2 | Lundbeck LLC ($342,375) |
| 2023 | $630,598 | 2 | Lundbeck LLC ($630,598) |
| 2022 | $889,133 | 2 | Lundbeck LLC ($889,133) |
| 2021 | $1.0M | 2 | Lundbeck LLC ($1.0M) |
| 2020 | $1.1M | 2 | Lundbeck LLC ($1.1M) |
| 2019 | $1.4M | 2 | Lundbeck LLC ($1.4M) |
| 2018 | $2.1M | 4 | Lundbeck LLC ($2.1M) |
| 2017 | $2.2M | 2 | Lundbeck LLC ($2.2M) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $230,686.56 | General |
| Category: NEUROLOGY | ||||||
| 04/24/2024 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $111,688.65 | General |
| Category: NEUROLOGY | ||||||
| 10/17/2023 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $285,406.78 | General |
| Category: NEUROLOGY | ||||||
| 04/25/2023 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $345,190.93 | General |
| Category: NEUROLOGY | ||||||
| 10/17/2022 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $434,882.35 | General |
| Category: NEUROLOGY | ||||||
| 06/29/2022 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $454,250.83 | General |
| Category: NEUROLOGY | ||||||
| 10/25/2021 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $481,618.92 | General |
| Category: NEUROLOGY | ||||||
| 04/22/2021 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $539,655.00 | General |
| Category: NEUROLOGY | ||||||
| 10/14/2020 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $586,668.90 | General |
| Category: NEUROLOGY | ||||||
| 04/27/2020 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $529,288.88 | General |
| Category: NEUROLOGY | ||||||
| 10/26/2019 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $542,032.80 | General |
| Category: NEUROLOGY | ||||||
| 04/22/2019 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $892,938.68 | General |
| Category: NEUROLOGY | ||||||
| 12/01/2018 | West Therapeutics Development, LLC | Cosyntropin (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 10/22/2018 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $980,753.02 | General |
| Category: NEUROLOGY | ||||||
| 10/15/2018 | West Therapeutics Development, LLC | Cosyntropin (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 04/13/2018 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $1,072,045.25 | General |
| Category: NEUROLOGY | ||||||
| 10/13/2017 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $1,094,625.80 | General |
| Category: NEUROLOGY | ||||||
| 04/10/2017 | Lundbeck LLC | SABRIL (Drug) | Royalty or License | Cash or cash equivalent | $1,071,890.95 | General |
| Category: NEUROLOGY | ||||||
About Dr. William Shields, M.D
Dr. William Shields, M.D is a Neurodevelopmental Disabilities healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821174442.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Shields, M.D has received a total of $9.7M in payments from pharmaceutical and medical device companies, with $342,375 received in 2024. These payments were reported across 18 transactions from 2 companies. The most common payment nature is "Royalty or License" ($9.7M).
Practice Information
- Specialty Neurodevelopmental Disabilities
- Location Los Angeles, CA
- Active Since 10/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080P0008X
- Entity Type Individual
- NPI Number 1821174442
Products in Payments
- SABRIL (Drug) $9.7M
- Cosyntropin (Drug) $2,100
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurodevelopmental Disabilities Doctors in Los Angeles
Raman Sankar, M.d, M.D
Neurodevelopmental Disabilities — Payments: $1.1M
Joyce Wu, M.d, M.D
Neurodevelopmental Disabilities — Payments: $42,273
Susan Perlman, Md, MD
Neurodevelopmental Disabilities — Payments: $29,551
Dr. Jason Lerner, M.d, M.D
Neurodevelopmental Disabilities — Payments: $12,156
Daniel Geschwind, Md, MD
Neurodevelopmental Disabilities — Payments: $10,472
Dr. Christopher Giza, M.d, M.D
Neurodevelopmental Disabilities — Payments: $6,790